# Keith D Lindor

## List of Publications by Year in Descending Order



| | | | |
|---|---|---|---|
| 280 papers | 23,148 citations | 84 h-index | 147 g-index |
| 300 ext. papers | 26,846 ext. citations | 7.2 avg, IF | 6.85 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 280 | A pilot study of vidofludimus calcium for treatment of primary sclerosing cholangitis.. *Hepatology Communications*, **2022**, | 6 | 1 |
| 279 | Liver Stiffness Measured by Either Magnetic Resonance or Transient Elastography Is Associated With Liver Fibrosis and Is an Independent Predictor of Outcomes Among Patients With Primary Biliary Cholangitis. *Journal of Clinical Gastroenterology*, **2021**, 55, 449-457 | 3 | 12 |
| 278 | Measurement of Gamma Glutamyl Transferase to Determine Risk of Liver Transplantation or Death in Patients With Primary Biliary Cholangitis. *Clinical Gastroenterology and Hepatology*, **2021**, 19, 1688-1697.e14 | 6.9 | 5 |
| 277 | Safety of fibrates in cholestatic liver diseases. *Liver International*, **2021**, 41, 1335-1343 | 7.9 | 2 |
| 276 | A Comparison of Prognostic Scores (Mayo, UK-PBC, and GLOBE) in Primary Biliary Cholangitis. *American Journal of Gastroenterology*, **2021**, 116, 1514-1522 | 0.7 | 1 |
| 275 | Global incidence, prevalence and features of primary sclerosing cholangitis: A systematic review and meta-analysis. *Liver International*, **2021**, 41, 2418-2426 | 7.9 | 4 |
| 274 | Successful response of primary sclerosing cholangitis and associated ulcerative colitis to oral vancomycin may depend on brand and personalized dose: report in an adolescent. *Clinical Journal of Gastroenterology*, **2021**, 14, 684-689 | 1.1 | 1 |
| 273 | Early Cholangiocarcinoma Detection With Magnetic Resonance Imaging Versus Ultrasound in Primary Sclerosing Cholangitis. *Hepatology*, **2021**, 73, 1868-1881 | 11.2 | 11 |
| 272 | Assessing and managing symptom burden and quality of life in primary sclerosing cholangitis patients. *Expert Opinion on Orphan Drugs*, **2021**, 9, 53-66 | 1.1 | |
| 271 | Dynamic Risk Prediction of Response to Ursodeoxycholic Acid Among Patients with Primary Biliary Cholangitis in the USA. *Digestive Diseases and Sciences*, **2021**, 1 | 4 | 1 |
| 270 | Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase. *American Journal of Gastroenterology*, **2020**, 115, 1066-1074 | 0.7 | 31 |
| 269 | Ursodeoxycholic Acid Treatment Preferentially Improves Overall Survival Among African Americans With Primary Biliary Cholangitis. *American Journal of Gastroenterology*, **2020**, 115, 262-270 | 0.7 | 6 |
| 268 | Primary Biliary Cholangitis: 2018 Practice Guidance From the American Association for the Study of Liver Diseases. *Clinical Liver Disease*, **2020**, 15, 1-2 | 2.2 | 6 |
| 267 | An update on primary sclerosing cholangitis epidemiology, outcomes and quantification of alkaline phosphatase variability in a population-based cohort. *Journal of Gastroenterology*, **2020**, 55, 523-532 | 6.9 | 10 |
| 266 | Simplified care-pathway selection for nonspecialist practice: the GLOBAL Primary Biliary Cholangitis Study Group Age, Bilirubin, Alkaline phosphatase risk assessment tool. *European Journal of Gastroenterology and Hepatology*, **2020**, 33, | 2.2 | 1 |
| 265 | Consensus guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury occurring during clinical trials in adults with chronic cholestatic liver disease. *Alimentary Pharmacology and Therapeutics*, **2020**, 51, 90-109 | 6.1 | 10 |
| 264 | Open-label prospective therapeutic clinical trials: oral vancomycin in children and adults with primary sclerosing cholangitis. *Scandinavian Journal of Gastroenterology*, **2020**, 55, 941-950 | 2.4 | 14 |

| | | | |
|---|---|---|---|
| 263 | The long-term outcomes of patients with immunoglobulin G4-related sclerosing cholangitis: the Mayo Clinic experience. *Journal of Gastroenterology*, **2020**, 55, 1087-1097 | 6.9 | 6 |
| 262 | Factors Associated With Progression and Outcomes of Early Stage Primary Biliary Cholangitis. *Clinical Gastroenterology and Hepatology*, **2020**, 18, 684-692.e6 | 6.9 | 10 |
| 261 | Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis. *Gut*, **2020**, 69, 1502-1509 | 19.2 | 13 |
| 260 | Efficacy and safety of curcumin in primary sclerosing cholangitis: an open label pilot study. *Scandinavian Journal of Gastroenterology*, **2019**, 54, 633-639 | 2.4 | 19 |
| 259 | Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis. *Clinical Gastroenterology and Hepatology*, **2019**, 17, 2076-2084.e2 | 6.9 | 27 |
| 258 | Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis. *Journal of Hepatology*, **2019**, 71, 357-365 | 13.4 | 80 |
| 257 | Current and promising therapy for primary biliary cholangitis. *Expert Opinion on Pharmacotherapy*, **2019**, 20, 1161-1167 | 4 | 7 |
| 256 | Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases. *Hepatology*, **2019**, 69, 394-419 | 11.2 | 224 |
| 255 | Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment response. *Alimentary Pharmacology and Therapeutics*, **2019**, 50, 1127-1136 | 6.1 | 29 |
| 254 | AGA Clinical Practice Update on Surveillance for Hepatobiliary Cancers in Patients With Primary Sclerosing Cholangitis: Expert Review. *Clinical Gastroenterology and Hepatology*, **2019**, 17, 2416-2422 | 6.9 | 31 |
| 253 | Cancer risk, screening and surveillance in primary sclerosing cholangitis. *Minerva Gastroenterologica E Dietologica*, **2019**, 65, 214-228 | 1.6 | 5 |
| 252 | Cancer risk in primary sclerosing cholangitis: Epidemiology, prevention, and surveillance strategies. *World Journal of Gastroenterology*, **2019**, 25, 659-671 | 5.6 | 44 |
| 251 | Potential Association of Doxycycline With the Onset of Primary Sclerosing Cholangitis: A Case Series. *American Journal of Therapeutics*, **2019**, | 1 | 2 |
| 250 | Design and Endpoints for Clinical Trials in Primary Sclerosing Cholangitis. *Hepatology*, **2018**, 68, 1174-1188 | 11.2 | 21 |
| 249 | Review article: the evidence that vancomycin is a therapeutic option for primary sclerosing cholangitis. *Alimentary Pharmacology and Therapeutics*, **2018**, 47, 886-895 | 6.1 | 41 |
| 248 | Increasing Prevalence of Primary Biliary Cholangitis and Reduced Mortality With Treatment. *Clinical Gastroenterology and Hepatology*, **2018**, 16, 1342-1350.e1 | 6.9 | 40 |
| 247 | Factors Associated With Prevalence and Treatment of Primary Biliary Cholangitis in United States Health Systems. *Clinical Gastroenterology and Hepatology*, **2018**, 16, 1333-1341.e6 | 6.9 | 26 |
| 246 | Complications, symptoms, quality of life and pregnancy in cholestatic liver disease. *Liver International*, **2018**, 38, 399-411 | 7.9 | 20 |

| | | | |
|---|---|---|---|
| 245 | Emerging therapeutic targets for primary sclerosing cholangitis. *Expert Opinion on Orphan Drugs*, **2018**, 6, 393-401 | 1.1 | |
| 244 | Antimitochondrial Antibody-Negative Primary Biliary Cholangitis: Is It Really the Same Disease?. *Clinics in Liver Disease*, **2018**, 22, 589-601 | 4.6 | 4 |
| 243 | Dominant strictures in primary sclerosing cholangitis: A multicenter survey of clinical definitions and practices. *Hepatology Communications*, **2018**, 2, 836-844 | 6 | 17 |
| 242 | Primary Sclerosing Cholangitis, Part 1: Epidemiology, Etiopathogenesis, Clinical Features, and Treatment. *Gastroenterology and Hepatology*, **2018**, 14, 293-304 | 0.7 | 6 |
| 241 | Primary Sclerosing Cholangitis, Part 2: Cancer Risk, Prevention, and Surveillance. *Gastroenterology and Hepatology*, **2018**, 14, 427-432 | 0.7 | 4 |
| 240 | Major Hepatic Complications in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis: Risk Factors and Time Trends in Incidence and Outcome. *American Journal of Gastroenterology*, **2018**, 113, 254-264 | 0.7 | 44 |
| 239 | Surveillance for hepatobiliary cancers in patients with primary sclerosing cholangitis. *Hepatology*, **2018**, 67, 2338-2351 | 11.2 | 56 |
| 238 | Primary sclerosing cholangitis in children versus adults: lessons for the clinic. *Expert Review of Gastroenterology and Hepatology*, **2018**, 12, 1025-1032 | 4.2 | 7 |
| 237 | Prospective Clinical Trial of Rifaximin Therapy for Patients With Primary Sclerosing Cholangitis. *American Journal of Therapeutics*, **2017**, 24, e56-e63 | 1 | 39 |
| 236 | A Randomized, Placebo-Controlled Clinical Trial of Efficacy and Safety: Modafinil in the Treatment of Fatigue in Patients With Primary Biliary Cirrhosis. *American Journal of Therapeutics*, **2017**, 24, e167-e176 | 1 | 33 |
| 235 | Update on pharmacotherapies for cholestatic liver disease. *Hepatology Communications*, **2017**, 1, 7-17 | 6 | 12 |
| 234 | Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis. *Gastroenterology*, **2017**, 152, 1975-1984.e8 | 13.3 | 219 |
| 233 | Emerging treatments for primary sclerosing cholangitis. *Expert Review of Gastroenterology and Hepatology*, **2017**, 11, 451-459 | 4.2 | 11 |
| 232 | Combination Therapy of All-Trans Retinoic Acid With Ursodeoxycholic Acid in Patients With Primary Sclerosing Cholangitis: A Human Pilot Study. *Journal of Clinical Gastroenterology*, **2017**, 51, e11-e16 | 3 | 29 |
| 231 | Old and new treatments for primary biliary cholangitis. *Liver International*, **2017**, 37, 490-499 | 7.9 | 30 |
| 230 | Clinical implications of serial versus isolated biliary fluorescence in situ hybridization (FISH) polysomy in primary sclerosing cholangitis. *Scandinavian Journal of Gastroenterology*, **2017**, 52, 377-381 | 2.4 | 20 |
| 229 | An update on cancer risk and surveillance in primary sclerosing cholangitis. *Liver International*, **2017**, 37, 1103-1109 | 7.9 | 27 |
| 228 | Curcumin in Hepatobiliary Disease: Pharmacotherapeutic Properties and Emerging Potential Clinical Applications. *Annals of Hepatology*, **2017**, 16, 835-841 | 3.1 | 28 |

| | | | |
|---|---|---|---|
| 227 | Investigational drugs in phase II clinical trials for primary biliary cholangitis. *Expert Opinion on Investigational Drugs*, **2017**, 26, 1115-1121 | 5.9 | 4 |
| 226 | Ursodeoxycholic Acid Treatment in Primary Sclerosing Cholangitis **2017**, 145-152 | | 4 |
| 225 | A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis. *New England Journal of Medicine*, **2016**, 375, 631-43 | 59.2 | 574 |
| 224 | Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study. *Gut*, **2016**, 65, 321-9 | 19.2 | 107 |
| 223 | Long-term outcomes in antimitochondrial antibody negative primary biliary cirrhosis. *Scandinavian Journal of Gastroenterology*, **2016**, 51, 745-52 | 2.4 | 22 |
| 222 | Emerging drugs for the treatment of Primary Biliary Cholangitis. *Expert Opinion on Emerging Drugs*, **2016**, 21, 39-56 | 3.7 | 14 |
| 221 | The management of autoimmunity in patients with cholestatic liver diseases. *Expert Review of Gastroenterology and Hepatology*, **2016**, 10, 73-91 | 4.2 | 8 |
| 220 | Alkaline phosphatase normalization is a biomarker of improved survival in primary sclerosing cholangitis. *Annals of Hepatology*, **2016**, 15, 246-53 | 3.1 | 27 |
| 219 | Oral Vancomycin Therapy in a Child with Primary Sclerosing Cholangitis and Severe Ulcerative Colitis. *Pediatric Gastroenterology, Hepatology and Nutrition*, **2016**, 19, 210-213 | 2.3 | 16 |
| 218 | Ustekinumab for patients with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid: A proof-of-concept study. *Hepatology*, **2016**, 64, 189-99 | 11.2 | 81 |
| 217 | Novel treatments in primary sclerosing cholangitis. *Clinical Liver Disease*, **2016**, 8, 132-135 | 2.2 | 1 |
| 216 | The Microbiome and Primary Sclerosing Cholangitis. *Seminars in Liver Disease*, **2016**, 36, 340-348 | 7.3 | 12 |
| 215 | Targets and investigative treatments for primary biliary cholangitis. *Expert Opinion on Orphan Drugs* , **2016**, 4, 1011-1020 | 1.1 | |
| 214 | Advances in primary sclerosing cholangitis. *The Lancet Gastroenterology and Hepatology*, **2016**, 1, 68-77 | 18.8 | 15 |
| 213 | Obeticholic acid for the treatment of primary biliary cholangitis. *Expert Opinion on Pharmacotherapy*, **2016**, 17, 1809-15 | 4 | 29 |
| 212 | Primary biliary cirrhosis: safety and benefits of established and emerging therapies. *Expert Opinion on Drug Safety*, **2015**, 14, 1435-44 | 4.1 | 6 |
| 211 | ACG Clinical Guideline: Primary Sclerosing Cholangitis. *American Journal of Gastroenterology*, **2015**, 110, 646-59; quiz 660 | 0.7 | 280 |
| 210 | Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy. *Gastroenterology*, **2015**, 149, 1804-1812.e4 | 13.3 | 235 |

| | | | |
|---|---|---|---|
| 209 | Changing nomenclature for PBC: From Cirrhosis to Cholangitis *Journal of Hepatology*, **2015**, 63, 1285-7 | 13.4 | 55 |
| 208 | Primary biliary cirrhosis. *Lancet, The*, **2015**, 386, 1565-75 | 40 | 325 |
| 207 | Unmet clinical need in autoimmune liver diseases. *Journal of Hepatology*, **2015**, 62, 208-18 | 13.4 | 44 |
| 206 | Changing nomenclature for PBC: From Cirrhosis to Cholangitis *Hepatology*, **2015**, 62, 1620-2 | 11.2 | 92 |
| 205 | Current research on the treatment of primary sclerosing cholangitis. *Intractable and Rare Diseases Research*, **2015**, 4, 1-6 | 1.4 | 23 |
| 204 | Changing nomenclature for PBC: From Cirrhosis to Cholangitis *Clinics and Research in Hepatology and Gastroenterology*, **2015**, 39, e57-9 | 2.4 | 29 |
| 203 | Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. *Gastroenterology*, **2015**, 148, 751-61.e8 | 13.3 | 381 |
| 202 | Novel therapeutic targets in primary biliary cirrhosis. *Nature Reviews Gastroenterology and Hepatology*, **2015**, 12, 147-58 | 24.2 | 94 |
| 201 | Recent advances in the development of farnesoid X receptor agonists. *Annals of Translational Medicine*, **2015**, 3, 5 | 3.2 | 92 |
| 200 | Commentary: Primary Sclerosing Cholangitis **2015**, 61-63 | | |
| 199 | Neoplasia in the ileoanal pouch following colectomy in patients with ulcerative colitis and primary sclerosing cholangitis. *Journal of Crohn's and Colitis*, **2014**, 8, 1294-9 | 1.5 | 19 |
| 198 | Obeticholic acid and budesonide for the treatment of primary biliary cirrhosis. *Expert Opinion on Pharmacotherapy*, **2014**, 15, 365-72 | 4 | 26 |
| 197 | Primary biliary cirrhosis in adults. *Expert Review of Gastroenterology and Hepatology*, **2014**, 8, 427-33 | 4.2 | 25 |
| 196 | Association between serum IgE level and adverse clinical endpoints in primary sclerosing cholangitis. *Annals of Hepatology*, **2014**, 13, 384-389 | 3.1 | 8 |
| 195 | Primary sclerosing cholangitis and the microbiota: current knowledge and perspectives on etiopathogenesis and emerging therapies. *Scandinavian Journal of Gastroenterology*, **2014**, 49, 901-8 | 2.4 | 63 |
| 194 | The natural history of primary biliary cirrhosis. *Seminars in Liver Disease*, **2014**, 34, 329-33 | 7.3 | 28 |
| 193 | An overview of current and future therapeutic strategies for the treatment of primary sclerosing cholangitis. *Expert Opinion on Orphan Drugs*, **2014**, 2, 545-556 | 1.1 | 1 |
| 192 | Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study. *Gastroenterology*, **2014**, 147, 1338-49.e5; quiz e15 | 13.3 | 265 |

| | | | |
|---|---|---|---|
| 191 | Association between serum IgE level and adverse clinical endpoints in primary sclerosing cholangitis. *Annals of Hepatology*, **2014**, 13, 384-9 | 3.1 | 7 |
| 190 | Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management. *Gastroenterology*, **2013**, 145, 521-36 | 13.3 | 290 |
| 189 | Primary sclerosing cholangitis. *Lancet, The*, **2013**, 382, 1587-99 | 40 | 370 |
| 188 | Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis - a pilot study. *Alimentary Pharmacology and Therapeutics*, **2013**, 37, 604-12 | 6.1 | 163 |
| 187 | Clinical management of autoimmune biliary diseases. *Journal of Autoimmunity*, **2013**, 46, 88-96 | 15.5 | 17 |
| 186 | Primary sclerosing cholangitis: a review and update on therapeutic developments. *Expert Review of Gastroenterology and Hepatology*, **2013**, 7, 103-14 | 4.2 | 46 |
| 185 | Role of the microbiota and antibiotics in primary sclerosing cholangitis. *BioMed Research International*, **2013**, 2013, 389537 | 3 | 64 |
| 184 | Pathogenesis and management of pruritus in cholestatic liver disease. *Journal of Gastroenterology and Hepatology (Australia)*, **2012**, 27, 1150-8 | 4 | 40 |
| 183 | Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. *Hepatology*, **2012**, 55, 512-21 | 11.2 | 107 |
| 182 | Long-term outcomes of patients with primary biliary cirrhosis and hepatocellular carcinoma. *Clinical Gastroenterology and Hepatology*, **2012**, 10, 182-5 | 6.9 | 20 |
| 181 | Optimizing biochemical markers as endpoints for clinical trials in primary biliary cirrhosis. *Liver International*, **2012**, 32, 790-5 | 7.9 | 45 |
| 180 | The safety and efficacy of oral docosahexaenoic acid supplementation for the treatment of primary sclerosing cholangitis - a pilot study. *Alimentary Pharmacology and Therapeutics*, **2012**, 35, 255-65 | 6.1 | 32 |
| 179 | Likelihood of malignancy in gallbladder polyps and outcomes following cholecystectomy in primary sclerosing cholangitis. *American Journal of Gastroenterology*, **2012**, 107, 431-9 | 0.7 | 59 |
| 178 | Recent developments in the management of idiopathic cholestatic liver disease. *Annals of Gastroenterology*, **2012**, 25, 317-326 | 2.2 | 1 |
| 177 | Challenges of Cholangiocarcinoma Detection in Patients with Primary Sclerosing Cholangitis. *Journal of Analytical Oncology*, **2012**, 1, 50-55 | | 14 |
| 176 | Colon neoplasms develop early in the course of inflammatory bowel disease and primary sclerosing cholangitis. *Clinical Gastroenterology and Hepatology*, **2011**, 9, 52-6 | 6.9 | 45 |
| 175 | Bone disease in patients with primary sclerosing cholangitis. *Gastroenterology*, **2011**, 140, 180-8 | 13.3 | 80 |
| 174 | Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis. *Digestive and Liver Disease*, **2011**, 43, 309-13 | 3.3 | 105 |

| | | | |
|---|---|---|---|
| 173 | Many patients with primary sclerosing cholangitis and increased serum levels of carbohydrate antigen 19-9 do not have cholangiocarcinoma. *Clinical Gastroenterology and Hepatology*, **2011**, 9, 434-9.e1 | 6.9 | 92 |
| 172 | Varices in early histological stage primary biliary cirrhosis. *Journal of Clinical Gastroenterology*, **2011**, 45, e66-71 | 3 | 31 |
| 171 | Antibiotics for the treatment of primary sclerosing cholangitis. *American Journal of Therapeutics*, **2011**, 18, 261-5 | 1 | 19 |
| 170 | Primary sclerosing cholangitis associated with elevated immunoglobulin G4: clinical characteristics and response to therapy. *American Journal of Therapeutics*, **2011**, 18, 198-205 | 1 | 96 |
| 169 | High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis. *Alimentary Pharmacology and Therapeutics*, **2011**, 34, 1185-92 | 6.1 | 59 |
| 168 | Cancer surveillance in patients with primary sclerosing cholangitis. *Hepatology*, **2011**, 54, 1842-52 | 11.2 | 204 |
| 167 | High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. *American Journal of Gastroenterology*, **2011**, 106, 1638-45 | 0.7 | 177 |
| 166 | New treatment strategies for primary sclerosing cholangitis. *Digestive Diseases*, **2011**, 29, 113-6 | 3.2 | 14 |
| 165 | Primary sclerosing cholangitis patients with serial polysomy fluorescence in situ hybridization results are at increased risk of cholangiocarcinoma. *American Journal of Gastroenterology*, **2011**, 106, 2023-8 | 0.7 | 83 |
| 164 | Pregnancy in primary sclerosing cholangitis. *Gut*, **2011**, 60, 1027-8 | 19.2 | 3 |
| 163 | Fatigue measurements in patients with primary biliary cirrhosis and the risk of mortality during follow-up. *Liver International*, **2010**, 30, 251-8 | 7.9 | 17 |
| 162 | The possible link between the thyroid and autoimmune liver diseases: reply. *Liver International*, **2010**, 30, 1240-1241 | 7.9 | 0 |
| 161 | Biliary Atresia and Cystic Fibrosis: Transitioning Care from Pediatrics to Internal Medicine **2010**, 164-171 | | |
| 160 | Acute Viral Hepatitis: Hepatitis A, Hepatitis E, and Other Viruses **2010**, 173-185 | | |
| 159 | Hepatitis B and C **2010**, 186-199 | | |
| 158 | Liver Transplantation: Early and Long Term Management and Complications **2010**, 327-346 | | |
| 157 | Bacterial and Other Non-Viral Infections of the Liver **2010**, 200-215 | | |
| 156 | Immunology of the Liver and Mechanisms of Inflammation **2010**, 17-22 | | |

| | | | |
|---|---|---|---|
| 155 | Cancer of the Gall Bladder and Biliary Tree **2010**, 374-382 | | |
| 154 | Assessment of Abnormal Liver Injury Tests **2010**, 32-37 | | |
| 153 | Endoscopic Techniques in Management of the Liver and Biliary Tree: Endoscopic Ultrasonography **2010**, 71-79 | | |
| 152 | Gall Stones, Gall-Bladder Polyps and Their Complications: Epidemiology, Pathogenesis, Diagnosis, and Management **2010**, 347-364 | | |
| 151 | Indications and Selection of Patients for Liver Transplantation **2010**, 297-304 | | |
| 150 | Endoscopic Techniques in Management of the Liver and Biliary Tree: Upper Gastrointestinal Endoscopy **2010**, 55-60 | | |
| 149 | Liver Mass Found on Abdominal Imaging **2010**, 95-104 | | |
| 148 | Autoimmune Liver Diseases **2010**, 250-260 | | |
| 147 | Vascular Diseases of the Liver **2010**, 261-274 | | 1 |
| 146 | Metabolic Liver Diseases **2010**, 216-223 | | |
| 145 | Hepatic Manifestations of Systemic Diseases **2010**, 288-295 | | |
| 144 | Autoimmune hepatitis-PBC overlap syndrome: a simplified scoring system may assist in the diagnosis. *American Journal of Gastroenterology*, **2010**, 105, 345-53 | 0.7 | 84 |
| 143 | Fatigue in primary biliary cirrhosis. *Nature Reviews Gastroenterology and Hepatology*, **2010**, 7, 313-9 | 24.2 | 32 |
| 142 | Is there a role for tetrathiomolybdate in the treatment of primary biliary cirrhosis?. *Translational Research*, **2010**, 155, 120-2 | 11 | 2 |
| 141 | Liver Biopsy and Paracentesis **2010**, 80-86 | | |
| 140 | Right Upper Quadrant Abdominal Pain **2010**, 105-112 | | |
| 139 | Hepatic Complications of Bone Marrow Transplantation **2010**, 275-287 | | |
| 138 | Jaundice and Pruritus: A Diagnostic Approach **2010**, 87-94 | | |

| | | | |
|---|---|---|---|
| 137 | Hepatic Steatosis and Non-Alcoholic Fatty Liver Disease **2010**, 224-234 | | |
| 136 | What Hepatologists Should Know about Liver Transplant Surgery **2010**, 305-316 | | |
| 135 | Approach to History Taking and Physical Examination in Liver and Biliary Disease **2010**, 23-31 | | |
| 134 | Drug-Induced Liver Injury **2010**, 235-242 | | |
| 133 | Imaging of the Liver and Biliary Tree **2010**, 38-54 | | |
| 132 | The Liver and Biliary Apparatus: Basic Structural Anatomy and Variations **2010**, 1-16 | | |
| 131 | Biliary Strictures and Leaks **2010**, 383-392 | | |
| 130 | Functional Gall-Bladder and Sphincter of Oddi Disorders **2010**, 365-373 | | |
| 129 | Immunosuppression in Liver Transplantation **2010**, 317-326 | | |
| 128 | Pregnancy and Liver Disease **2010**, 152-163 | | |
| 127 | Moexipril for treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid. *Digestive Diseases and Sciences*, **2010**, 55, 476-83 | 4 | 9 |
| 126 | Long-term outcomes of positive fluorescence in situ hybridization tests in primary sclerosing cholangitis. *Hepatology*, **2010**, 51, 174-80 | 11.2 | 134 |
| 125 | Reply: Diagnostic Utility of Chromosome 17 and p16 Abnormalities in Fluorescence In Situ Hybridization Tests in Primary Sclerosing Cholangitis. *Hepatology*, **2010**, 52, 394-395 | 11.2 | |
| 124 | Linking medical education and patient care. *Minnesota Medicine*, **2010**, 93, 32, 34 | 0.3 | |
| 123 | Minocycline in the treatment of patients with primary sclerosing cholangitis: results of a pilot study. *American Journal of Gastroenterology*, **2009**, 104, 83-8 | 0.7 | 90 |
| 122 | Primary biliary cirrhosis. *Hepatology*, **2009**, 50, 291-308 | 11.2 | 875 |
| 121 | High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. *Hepatology*, **2009**, 50, 808-14 | 11.2 | 459 |
| 120 | B-cell depletion with anti-CD20 ameliorates autoimmune cholangitis but exacerbates colitis in transforming growth factor-beta receptor II dominant negative mice. *Hepatology*, **2009**, 50, 1893-903 | 11.2 | 75 |

| | | | |
|---|---|---|---|
| 119 | Review article: nuclear receptors and liver disease--current understanding and new therapeutic implications. *Alimentary Pharmacology and Therapeutics*, **2009**, 30, 816-25 | 6.1 | 12 |
| 118 | Clinical trial: randomized controlled study of zidovudine and lamivudine for patients with primary biliary cirrhosis stabilized on ursodiol. *Alimentary Pharmacology and Therapeutics*, **2008**, 28, 886-94 | 6.1 | 42 |
| 117 | Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. *Gastroenterology*, **2008**, 134, 706-15 | 13.3 | 671 |
| 116 | Antimitochondrial antibody-negative primary biliary cirrhosis. *Gastroenterology Clinics of North America*, **2008**, 37, 479-84, viii | 4.4 | 28 |
| 115 | Clinical features and management of primary sclerosing cholangitis. *World Journal of Gastroenterology*, **2008**, 14, 3338-49 | 5.6 | 44 |
| 114 | Primary sclerosing cholangitis. *Canadian Journal of Gastroenterology & Hepatology*, **2008**, 22, 689-98 | | 58 |
| 113 | Impact of inflammatory bowel disease and ursodeoxycholic acid therapy on small-duct primary sclerosing cholangitis. *Hepatology*, **2008**, 47, 133-42 | 11.2 | 27 |
| 112 | Silymarin in the treatment of patients with primary sclerosing cholangitis: an open-label pilot study. *Digestive Diseases and Sciences*, **2008**, 53, 1716-20 | 4 | 29 |
| 111 | Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis. *Hepatology*, **2008**, 48, 1106-17 | 11.2 | 259 |
| 110 | Surveillance for hepatocellular carcinoma in patients with primary biliary cirrhosis. *Hepatology*, **2008**, 48, 1149-56 | 11.2 | 51 |
| 109 | Clinical predictors for hepatocellular carcinoma in patients with primary biliary cirrhosis. *Clinical Gastroenterology and Hepatology*, **2007**, 5, 259-64 | 6.9 | 42 |
| 108 | Immunoglobulin G4 associated cholangitis: description of an emerging clinical entity based on review of the literature. *Hepatology*, **2007**, 45, 1547-54 | 11.2 | 195 |
| 107 | Increased prevalence of antimitochondrial antibodies in first-degree relatives of patients with primary biliary cirrhosis. *Hepatology*, **2007**, 46, 785-92 | 11.2 | 106 |
| 106 | Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation. *Liver Transplantation*, **2007**, 13, 1236-45 | 4.5 | 137 |
| 105 | Development of autoimmune hepatitis in primary biliary cirrhosis. *Liver International*, **2007**, 27, 1086-90 | 7.9 | 43 |
| 104 | Overlap of autoimmune hepatitis and primary biliary cirrhosis: long-term outcomes. *American Journal of Gastroenterology*, **2007**, 102, 1244-50 | 0.7 | 110 |
| 103 | Ursodeoxycholic acid for the treatment of primary biliary cirrhosis. *New England Journal of Medicine* , **2007**, 357, 1524-9 | 59.2 | 78 |
| 102 | Elevated serum IgG4 concentration in patients with primary sclerosing cholangitis. *American Journal of Gastroenterology*, **2006**, 101, 2070-5 | 0.7 | 280 |

| | | | |
|---|---|---|---|
| 101 | Fluoxetine for the treatment of fatigue in primary biliary cirrhosis: a randomized, double-blind controlled trial. *Digestive Diseases and Sciences*, **2006**, 51, 1985-91 | 4 | 41 |
| 100 | Mycophenolate Mofetil for the Treatment of Primary Biliary Cirrhosis in Patients with an Incomplete Response to Ursodeoxycholic Acid. *Journal of Clinical Gastroenterology*, **2005**, 39, 838 | 3 | 34 |
| 99 | Primary sclerosing cholangitis. *Inflammatory Bowel Diseases*, **2005**, 11, 62-72 | 4.5 | 85 |
| 98 | Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo-controlled trial. *Hepatology*, **2005**, 42, 762-71 | 11.2 | 117 |
| 97 | Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients. *Hepatology*, **2005**, 42, 1194-202 | 11.2 | 448 |
| 96 | The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis. *Digestive Diseases and Sciences*, **2005**, 50, 1734-40 | 4 | 243 |
| 95 | Mycophenolate mofetil for the treatment of primary sclerosing cholangitis. *American Journal of Gastroenterology*, **2005**, 100, 308-12 | 0.7 | 58 |
| 94 | Mycophenolate mofetil for the treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid. *Journal of Clinical Gastroenterology*, **2005**, 39, 168-71 | 3 | 24 |
| 93 | Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. *American Journal of Gastroenterology*, **2004**, 99, 523-6 | 0.7 | 413 |
| 92 | Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. *Hepatology*, **2004**, 39, 770-8 | 11.2 | 549 |
| 91 | Cost-minimization analysis of MRC versus ERCP for the diagnosis of primary sclerosing cholangitis. *Hepatology*, **2004**, 40, 39-45 | 11.2 | 90 |
| 90 | Do antinuclear antibodies in primary biliary cirrhosis patients identify increased risk for liver failure?. *Clinical Gastroenterology and Hepatology*, **2004**, 2, 1116-22 | 6.9 | 62 |
| 89 | Is there a role for liver biopsy in primary sclerosing cholangitis?. *American Journal of Gastroenterology*, **2003**, 98, 1155-8 | 0.7 | 109 |
| 88 | Treatment with ursodeoxycholic acid is associated with weight gain in patients with primary biliary cirrhosis. *Journal of Clinical Gastroenterology*, **2003**, 37, 183-5 | 3 | 28 |
| 87 | Primary sclerosing cholangitis in children: a long-term follow-up study. *Hepatology*, **2003**, 38, 210-7 | 11.2 | 175 |
| 86 | Natural history of pruritus in primary biliary cirrhosis. *Clinical Gastroenterology and Hepatology*, **2003**, 1, 297-302 | 6.9 | 80 |
| 85 | When is liver biopsy needed in the diagnosis of primary biliary cirrhosis?. *Clinical Gastroenterology and Hepatology*, **2003**, 1, 89-95 | 6.9 | 56 |
| 84 | Management of osteoporosis, fat-soluble vitamin deficiencies, and hyperlipidemia in primary biliary cirrhosis. *Clinics in Liver Disease*, **2003**, 7, 901-10 | 4.6 | 30 |

| | | | |
|---|---|---|---|
| 83 | Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. *Gastroenterology*, **2003**, 124, 889-93 | 13.3 | 446 |
| 82 | Primary biliary cirrhosis. *Lancet, The*, **2003**, 362, 53-61 | 40 | 269 |
| 81 | Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis. *Journal of Hepatology*, **2003**, 39, 12-6 | 13.4 | 163 |
| 80 | Pirfenidone in the treatment of primary sclerosing cholangitis. *Digestive Diseases and Sciences*, **2002**, 47, 157-61 | 4 | 45 |
| 79 | Primary biliary cirrhosis with additional features of autoimmune hepatitis: response to therapy with ursodeoxycholic acid. *Hepatology*, **2002**, 35, 409-13 | 11.2 | 128 |
| 78 | Small-duct primary sclerosing cholangitis: a long-term follow-up study. *Hepatology*, **2002**, 35, 1494-500 | 11.2 | 146 |
| 77 | In primary sclerosing cholangitis, gallbladder polyps are frequently malignant. *American Journal of Gastroenterology*, **2002**, 97, 1138-42 | 0.7 | 130 |
| 76 | Overlap of autoimmune hepatitis and primary biliary cirrhosis: an evaluation of a modified scoring system. *American Journal of Gastroenterology*, **2002**, 97, 1191-7 | 0.7 | 98 |
| 75 | Pregnancy in a patient with primary sclerosing cholangitis. *Journal of Clinical Gastroenterology*, **2002**, 35, 353-5 | 3 | 21 |
| 74 | Human leukocyte antigen Class II associations in serum antimitochondrial antibodies (AMA)-positive and AMA-negative primary biliary cirrhosis. *Journal of Hepatology*, **2002**, 36, 8-13 | 13.4 | 35 |
| 73 | Nutritional and metabolic considerations in the etiology of nonalcoholic steatohepatitis. *Digestive Diseases and Sciences*, **2001**, 46, 2347-52 | 4 | 118 |
| 72 | Incomplete response to ursodeoxycholic acid in primary biliary cirrhosis: is a double dosage worthwhile?. *American Journal of Gastroenterology*, **2001**, 96, 3152-7 | 0.7 | 35 |
| 71 | High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis. *American Journal of Gastroenterology*, **2001**, 96, 1558-62 | 0.7 | 172 |
| 70 | Balloon dilation compared to stenting of dominant strictures in primary sclerosing cholangitis. *American Journal of Gastroenterology*, **2001**, 96, 1059-66 | 0.7 | 161 |
| 69 | Fat-soluble vitamin levels in patients with primary biliary cirrhosis. *American Journal of Gastroenterology*, **2001**, 96, 2745-50 | 0.7 | 90 |
| 68 | Bone disease in primary biliary cirrhosis: independent indicators and rate of progression. *Journal of Hepatology*, **2001**, 35, 316-23 | 13.4 | 131 |
| 67 | Medical treatment for primary sclerosing cholangitis: risk versus benefit. *Hepatology*, **2000**, 32, 871-2 | 11.2 | 4 |
| 66 | A Revised Natural History Model for Primary Sclerosing Cholangitis. *Mayo Clinic Proceedings*, **2000**, 75, 688-694 | 6.4 | 203 |

| | | | |
|---|---|---|---|
| 65 | Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. *Hepatology*, **2000**, 31, 318-23 | 11.2 | 148 |
| 64 | Silymarin in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. *Hepatology*, **2000**, 32, 897-900 | 11.2 | 61 |
| 63 | Reliability and validity of the NIDDK-QA instrument in the assessment of quality of life in ambulatory patients with cholestatic liver disease. *Hepatology*, **2000**, 32, 924-9 | 11.2 | 33 |
| 62 | Metabolic and nutritional considerations in nonalcoholic fatty liver. *Hepatology*, **2000**, 32, 3-10 | 11.2 | 145 |
| 61 | Management of primary biliary cirrhosis: from diagnosis to end-stage disease. *Current Gastroenterology Reports*, **2000**, 2, 94-8 | 5 | 4 |
| 60 | Medical management of chronic cholestatic liver diseases. *Canadian Journal of Gastroenterology & Hepatology*, **2000**, 14 Suppl D, 93D-98D | | 1 |
| 59 | A pilot study of pentoxifylline for the treatment of primary sclerosing cholangitis. *American Journal of Gastroenterology*, **2000**, 95, 2338-42 | 0.7 | 68 |
| 58 | Oral budesonide in the treatment of primary sclerosing cholangitis. *American Journal of Gastroenterology*, **2000**, 95, 2333-7 | 0.7 | 117 |
| 57 | A revised natural history model for primary sclerosing cholangitis. *Mayo Clinic Proceedings*, **2000**, 75, 688-94 | 6.4 | 221 |
| 56 | Epidemiology and natural history of primary biliary cirrhosis in a US community. *Gastroenterology*, **2000**, 119, 1631-6 | 13.3 | 278 |
| 55 | Overlap of autoimmune hepatitis and primary sclerosing cholangitis: an evaluation of a modified scoring system. *Journal of Hepatology*, **2000**, 33, 537-542 | 13.4 | 99 |
| 54 | Etidronate for osteoporosis in primary biliary cirrhosis: a randomized trial. *Journal of Hepatology*, **2000**, 33, 878-82 | 13.4 | 64 |
| 53 | Overlap of autoimmune hepatitis and primary sclerosing cholangitis: an evaluation of a modified scoring system. *Journal of Hepatology*, **2000**, 33, 537-42 | 13.4 | 133 |
| 52 | Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid. *Liver International*, **1999**, 19, 115-21 | 7.9 | 135 |
| 51 | Oral nicotine in treatment of primary sclerosing cholangitis: a pilot study. *Digestive Diseases and Sciences*, **1999**, 44, 602-7 | 4 | 55 |
| 50 | Primary Biliary Cirrhosis. *Current Treatment Options in Gastroenterology*, **1999**, 2, 473-480 | 2.5 | 1 |
| 49 | Clinical significance of serum bilirubin levels under ursodeoxycholic acid therapy in patients with primary biliary cirrhosis. *Hepatology*, **1999**, 29, 39-43 | 11.2 | 70 |
| 48 | Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis. *Hepatology*, **1999**, 29, 644-7 | 11.2 | 186 |

| | | | |
|---|---|---|---|
| 47 | Incidence of cancer in primary biliary cirrhosis: the Mayo experience. *Hepatology*, **1999**, 29, 1396-8 | 11.2 | 85 |
| 46 | The relative role of the Child-Pugh classification and the Mayo natural history model in the assessment of survival in patients with primary sclerosing cholangitis. *Hepatology*, **1999**, 29, 1643-8 | 11.2 | 104 |
| 45 | Primary sclerosing cholangitis. *Hepatology*, **1999**, 30, 325-32 | 11.2 | 196 |
| 44 | Ursodeoxycholic acid as adjunctive therapy for problematic type 1 autoimmune hepatitis: a randomized placebo-controlled treatment trial. *Hepatology*, **1999**, 30, 1381-6 | 11.2 | 112 |
| 43 | Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. *Hepatology*, **1999**, 30, 1356-62 | 11.2 | 1236 |
| 42 | Effect of pretransplantation ursodeoxycholic acid therapy on the outcome of liver transplantation in patients with primary biliary cirrhosis. *Liver Transplantation*, **1999**, 5, 269-74 | | 19 |
| 41 | Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial. *Journal of Hepatology*, **1999**, 30, 830-5 | 13.4 | 99 |
| 40 | Cost-effectiveness of ultrasound-guided liver biopsy. *Hepatology*, **1998**, 27, 1220-6 | 11.2 | 117 |
| 39 | Bone disease in patients with primary sclerosing cholangitis: prevalence, severity and prediction of progression. *Journal of Hepatology*, **1998**, 29, 729-35 | 13.4 | 102 |
| 38 | Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. *New England Journal of Medicine*, **1997**, 336, 691-5 | 59.2 | 478 |
| 37 | Interactions Between Chronic Liver Disease and Inflammatory Bowel Disease. *Inflammatory Bowel Diseases*, **1997**, 3, 288-302 | 4.5 | 43 |
| 36 | Ursodeoxycholic acid delays the onset of esophageal varices in primary biliary cirrhosis. *Mayo Clinic Proceedings*, **1997**, 72, 1137-40 | 6.4 | 122 |
| 35 | Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. *Gastroenterology*, **1997**, 113, 884-90 | 13.3 | 517 |
| 34 | Review: nonalcoholic steatohepatitis. *Journal of Gastroenterology and Hepatology (Australia)*, **1997**, 12, 398-403 | 4 | 147 |
| 33 | Does antimitochondrial antibody status affect response to treatment in patients with primary biliary cirrhosis? Outcomes of ursodeoxycholic acid therapy and liver transplantation. *Hepatology*, **1997**, 26, 22-6 | 11.2 | 86 |
| 32 | Early primary biliary cirrhosis: just delayed or different?. *Hepatology*, **1997**, 26, 239-41 | 11.2 | 13 |
| 31 | Interactions Between Chronic Liver Disease and Inflammatory Bowel Disease. *Inflammatory Bowel Diseases*, **1997**, 3, 288-302 | 4.5 | 49 |
| 30 | Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis. *Gastroenterology*, **1996**, 110, 1515-8 | 13.3 | 179 |

| | | | |
|---|---|---|---|
| 29 | Time course of histological progression in primary biliary cirrhosis. *Hepatology*, **1996**, 23, 52-6 | 11.2 | 143 |
| 28 | Time course of histological progression in primary biliary cirrhosis **1996**, 23, 52 | | 3 |
| 27 | Ursodeoxycholic acid and methotrexate for primary sclerosing cholangitis: a pilot study. *American Journal of Gastroenterology*, **1996**, 91, 511-5 | 0.7 | 60 |
| 26 | Effects of ursodeoxycholic acid on hepatic inflammation and histological stage in patients with primary biliary cirrhosis. *American Journal of Gastroenterology*, **1996**, 91, 2314-7 | 0.7 | 26 |
| 25 | Characterisation of patients with a complete biochemical response to ursodeoxycholic acid. *Gut*, **1995**, 36, 935-8 | 19.2 | 57 |
| 24 | The combination of ursodeoxycholic acid and methotrexate for patients with primary biliary cirrhosis: the results of a pilot study. *Hepatology*, **1995**, 22, 1158-62 | 11.2 | 67 |
| 23 | Colchicine and ursodeoxycholic acid for primary biliary cirrhosis: emerging results. *Gastroenterology* , **1995**, 108, 1592-4 | 13.3 | 3 |
| 22 | Serum lipid and fat-soluble vitamin levels in primary sclerosing cholangitis. *Journal of Clinical Gastroenterology*, **1995**, 20, 215-9 | 3 | 65 |
| 21 | Bone disease in primary biliary cirrhosis: Does ursodeoxycholic acid make a difference?. *Hepatology*, **1995**, 21, 389-392 | 11.2 | 89 |
| 20 | The combination of ursodeoxycholic acid and methotrexate for patients with primary biliary cirrhosis: The results of a pilot study. *Hepatology*, **1995**, 22, 1158-1162 | 11.2 | 53 |
| 19 | Bone disease in primary biliary cirrhosis: does ursodeoxycholic acid make a difference?. *Hepatology*, **1995**, 21, 389-92 | 11.2 | 83 |
| 18 | Antimitochondrial antibody-negative primary biliary cirrhosis. *American Journal of Gastroenterology*, **1995**, 90, 247-9 | 0.7 | 107 |
| 17 | Primary biliary cirrhosis. *Revista De Gastroenterologí De Méxíco*, **1995**, 60, S75-7 | 0.7 | |
| 16 | Primary sclerosing cholangitis. *Revista De Gastroenterologí De Méxíco*, **1995**, 60, S78-80 | 0.7 | |
| 15 | Chronic cholestasis in a young man. *Hepatology*, **1994**, 20, 1351-1355 | 11.2 | 6 |
| 14 | Effect of ursodeoxycholic acid on serum lipids of patients with primary biliary cirrhosis. *Mayo Clinic Proceedings*, **1994**, 69, 923-9 | 6.4 | 39 |
| 13 | Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. *Gastroenterology*, **1994**, 106, 1284-90 | 13.3 | 397 |
| 12 | The natural history of abdominal pain associated with primary biliary cirrhosis. *American Journal of Gastroenterology*, **1994**, 89, 1840-3 | 0.7 | 18 |

| | | | |
|---|---|---|---|
| 11 | Chronic cholestasis in a young man **1994**, 20, 1351 | | 3 |
| 10 | Hypercholesterolemia and atherosclerosis in primary biliary cirrhosis: what is the risk?. *Hepatology*, **1992**, 15, 858-62 | 11.2 | 152 |
| 9 | The metabolic bone disease of primary sclerosing cholangitis. *Hepatology*, **1991**, 14, 257-261 | 11.2 | 95 |
| 8 | The combination of prednisone and colchicine in patients with primary sclerosing cholangitis. *American Journal of Gastroenterology*, **1991**, 86, 57-61 | 0.7 | 77 |
| 7 | The metabolic bone disease of primary sclerosing cholangitis **1991**, 14, 257 | | 6 |
| 6 | A controlled trial of cyclosporine in the treatment of primary biliary cirrhosis. *New England Journal of Medicine*, **1990**, 322, 1419-24 | 59.2 | 169 |
| 5 | Clinical and statistical analyses of new and evolving therapies for primary biliary cirrhosis. *Hepatology*, **1988**, 8, 668-76 | 11.2 | 54 |
| 4 | The autologous mixed lymphocyte reaction in primary biliary cirrhosis: analysis of activation and blastogenesis of autoreactive T lymphocytes. *Hepatology*, **1988**, 8, 1555-9 | 11.2 | 15 |
| 3 | Enhanced autoreactivity of T-lymphocytes in primary sclerosing cholangitis. *Hepatology*, **1987**, 7, 884-8 | 11.2 | 52 |
| 2 | Endoscopic Techniques in Management of the Liver and Biliary Tree: Endoscopic Retrograde Cholangiopancreatography and Biliary Manometry61-70 | | |
| 1 | Is there Still a Role for Ursodeoxycholic Acid Treatment in Patients with Inflammatory Bowel Disease Associated with Primary Sclerosing Cholangitis?156-158 | | |